PDF(Pubmed)
Abstract：
Rosacea, a chronic skin condition affecting millions of people in the USA, leads to significant social and professional stigmatization. Effective management strategies are crucial to alleviate symptoms and improve patients\' quality of life. Encapsulated benzoyl peroxide 5% (E-BPO 5%) is a newly FDA-approved topical treatment for rosacea that shows promise in enhancing therapeutic response and minimizing skin irritation. This review aims to assess the role of recently FDA approved E-BPO 5% in the current treatment landscape for rosacea management, as it is not yet included in clinical guidelines that predominantly rely on older approved therapies. The review focuses on randomized controlled trials conducted in English-speaking adults. It evaluates the efficacy, safety, and tolerability of various US Food and Drug Administration (FDA)-approved agents used for rosacea treatment, including E-BPO cream, metronidazole gel, azelaic acid gel and foam, ivermectin cream, minocycline foam, oral doxycycline, brimonidine gel, and oxymetazoline HCl cream. Existing therapies have been effective in reducing papulopustular lesions and erythema associated with rosacea for many years. E-BPO 5% offers a promising addition to the treatment options due to its microencapsulation technology, which prolongs drug delivery time and aims to improve therapeutic response while minimizing skin irritation. Further research is necessary to determine the exact role of E-BPO 5% in the therapeutic landscape for rosacea. However, based on available evidence, E-BPO 5% shows potential as a valuable treatment option for managing inflammatory lesions of rosacea, and it may offer benefits to patients including: rapid onset of action, demonstrated efficacy by Week 2, excellent tolerability, and sustained long-term results for up to 52 weeks of treatment.
摘要：
酒渣鼻,一种影响美国数百万人的慢性皮肤病，导致严重的社会和职业污名化。有效的管理策略对于缓解症状和提高患者的生活质量至关重要。包封的过氧化苯甲酰5％（E-BPO5％）是一种新的FDA批准的局部治疗酒渣鼻，显示在提高治疗反应和减少皮肤刺激的希望。这篇评论旨在评估最近FDA批准的E-BPO5％在当前治疗领域的酒渣鼻管理中的作用。因为它尚未被纳入主要依赖较早批准的疗法的临床指南。该综述侧重于在讲英语的成年人中进行的随机对照试验。它评估疗效，安全,以及美国食品和药物管理局（FDA）批准的用于酒渣鼻治疗的各种药物的耐受性，包括E-BPO霜,甲硝唑凝胶，壬二酸凝胶和泡沫，伊维菌素乳膏,米诺环素泡沫，口服多西环素，溴莫尼定凝胶,和盐酸羟甲唑啉乳膏。多年来，现有的疗法已有效减少与酒渣鼻相关的丘疹脓疱病变和红斑。由于其微囊化技术，E-BPO5％为治疗选择提供了有希望的补充，延长药物输送时间，旨在改善治疗反应，同时最大限度地减少皮肤刺激。需要进一步的研究来确定E-BPO5％在酒渣鼻治疗中的确切作用。然而,根据现有证据,E-BPO5％显示作为管理酒渣鼻炎性病变的有价值的治疗选择的潜力，它可能给患者带来好处，包括:快速起效，到第2周时表现出疗效，具有出色的耐受性，并持续52周的长期治疗结果。
